RDY

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ovarian cancer, Patient, Lung cancer, Bevacizumab, RDY, Cancer, Generic drug

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr.

Key Points: 
  • Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr.
  • Reddy’s”), a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
  • Versavo® is the first Dr. Reddy’s biosimilar product to be approved and launched in the UK.
  • Subsequently, Versavo® was introduced in other markets such as Thailand, Ukraine, Nepal, and Jamaica under the same brand name.

iBUYPOWER Signs on as Official Partner and PC of VALORANT Champions Tour Americas

Retrieved on: 
Wednesday, February 14, 2024
SSD, NVM Express, LOS, Nvidia, Ryzen, Valorant Champions Tour, Partnership, Official, ACE, DDR5, TB, Y40, VCT, Gold, FPS, MSRP, Riot Games, Personal computer, RDY, OCCT, RAM, NVIDIA, Video game

LOS ANGELES, Feb. 14, 2024 /PRNewswire/ -- iBUYPOWER, a leading manufacturer of high-performance custom gaming PCs, today announced it has become the official PC of VALORANT Champions Tour (VCT) Americas, VCT Game Changers North America, and VCT Game Changers Brazil. As iBUYPOWER celebrates its 25th anniversary, the partnership amplifies and highlights iBUYPOWER's dedication and integral role in supporting esports players with quality and reliable tools to succeed in their craft.

Key Points: 
  • The partnership highlights iBUYPOWER's top-tier PC hardware commitment for VALORANT Champions Tour (VCT) Americas International League, VCT Game Changers North America, and VCT Game Changers Brazil esports leagues.
  • LOS ANGELES, Feb. 14, 2024 /PRNewswire/ -- iBUYPOWER, a leading manufacturer of high-performance custom gaming PCs, today announced it has become the official PC of VALORANT Champions Tour (VCT) Americas, VCT Game Changers North America, and VCT Game Changers Brazil.
  • For VALORANT Americas pros and fans looking for the gold standard PC experience and wanting to frag like their favorite team, iBUYPOWER will make available a series of Official VCT Americas 'Spec-Approved' PCs.
  • To learn more about the Official VCT Americas 'Spec-Approved' PCs from iBUYPOWER, please visit: https://www.ibuypower.com/community/partners/riotgames/valorant-champion...
    To learn more about VCT Americas, please visit:

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands

Retrieved on: 
Wednesday, January 3, 2024
Health, Consumer, Women, Fitness & Nutrition, General Health, Vitamins, Supplements, Well, Menopause, Acquisition, Amazon, Probiotic, Education, Laboratory, Ageing, Goodness, Walmart, Growth, Dietary supplement, RDY

Dr. Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause.

Key Points: 
  • Dr. Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause.
  • Brands include MenoFit™ and MenoGlow™ probiotics, Happy Fiber™ and Well Rested™ dietary supplements, Athena’s Shield™ menopause support supplement, and Goodness Glow™ and Keep Glowing Gorgeous™ supplements for healthy aging support.
  • The deal also includes the MenoLife® health tracker app which supports the product line and provides community, education, and information to consumers regarding menopause.
  • MenoLabs portfolio of products is sold in the United States, primarily through the brand’s own [ https://menolabs.com ] and other e-commerce marketplaces including Amazon and Walmart.

iBUYPOWER and DeepCool Announce Partnership with Custom and Ready to Ship RDY Gaming PCs

Retrieved on: 
Tuesday, December 19, 2023
Personal computer, Partnership, AIO, Intel, USD, LOS, MSRP, Deepcool, RDY, PC, Video game

LOS ANGELES, Dec. 19, 2023 /PRNewswire-PRWeb/ -- iBUYPOWER, a leading systems integrator of high-performance custom gaming PCs is expanding its product offering with DeepCool, an award-winning manufacturer of high-performance PC hardware and thermal solutions known for its innovative design and exceptional quality.

Key Points: 
  • "Forming a long-term partnership with DeepCool represents our commitment to building PCs with quality components, especially with our iBUYPOWER branded AIO coolers," said King Perez de Tagle, Marketing Executive Producer of HYTE and iBUYPOWER.
  • "We're proud to launch a number of RDYs and Configurators with DeepCool moving forward."
  • Integrating DeepCool hardware into iBUYPOWER systems is a pivotal move in providing consumers with cooling solutions that meet the demands of modern hardware for long-lasting performance.
  • With DeepCool, iBUYPOWER is launching two ready-to-ship RDY SKUs, the Lancool 001 and the Y40P 001.

Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Retrieved on: 
Thursday, December 14, 2023
Health, Environment, Sustainability, Clinical Trials, Pharmaceutical, Biotechnology, NYSE, Ethics, Climate, Labour, DJSI, Standard, Patient, Innovation management, Dow Jones, ISO, Nature, BSE, Agroforestry, Pharmaceutical industry in India, GRI, United Nations Global Compact, Human rights, WEF, NSE, RDY, Access, Sustainable procurement, ESG, Circularity, Health care

Reddy’s”), a global pharmaceutical company, has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda.

Key Points: 
  • Reddy’s”), a global pharmaceutical company, has won back-to-back global recognitions for its commitment and progress on sustainability and Environment Social and Governance (ESG) agenda.
  • Dr. Reddy’s has become the first Indian pharma company to earn a place in the Standard & Poor Dow Jones Sustainability World Index (DJSI World) for 2023.
  • Alongside its debut in DJSI World, the company retains its place in the Dow Jones Sustainability Index for Emerging Markets (DJSI EM) for the 8th year in a row.
  • The DJSI recognitions are based on Dr. Reddy’s performance in the Standard & Poor Global Corporate Sustainability Assessment (S&P Global CSA) and additional screening criteria.

Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, December 6, 2023
Research, Infectious Diseases, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, Science, NYSE, IND, Laboratory, COYA, Patient, Amyotrophy, Agreement, European, FDA, USD, BSE, Houston Methodist Hospital, Neurodegenerative disease, Partnership, NSE, RDY, Abatacept, Pharmaceutical industry, ALS, Coya

Reddy’s”), and Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Key Points: 
  • Reddy’s”), and Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”), today announced that they have entered into a development and license agreement (the “Agreement”) for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).
  • This Agreement is in addition to the in-licensing agreement with Dr. Reddy’s signed in early 20231.
  • Coya retains the right to commercialize COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America.
  • Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the United States.

Laffer Tengler Investments Named to PSN Top Guns List of Best Performing Strategies for Q2 2023

Retrieved on: 
Monday, August 28, 2023
Asset Management, Professional Services, Finance, SMA, Gun, RDY, Zephyr, ETF, CIO, Growth, SVP, PSN, Security (finance)

Laffer Tengler Investments, Inc. was named to the PSN Top Guns List of best performing separate accounts, managed accounts, and managed ETF strategies for Q2 2023.

Key Points: 
  • Laffer Tengler Investments, Inc. was named to the PSN Top Guns List of best performing separate accounts, managed accounts, and managed ETF strategies for Q2 2023.
  • The quarterly rankings, published by Zephyr on August 18, 2023, remain one of the most utilized references for investors and asset managers.
  • The Laffer Tengler Equity Income Strategy invests in high-quality, large-cap stocks with strong growth potential and an above-market dividend yield.
  • The complete list of PSN Top Guns and an overview of the methodology can be located at https://psn.fi.informais.com/ .

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, FDA, Pharmaceutical, Health, Steps, Eosinophilia–myalgia syndrome, BSE, Laboratory, Risk factor, Food and Drug Administration, Hypotension, Somnolence, Hypothermia, USFDA, Bradycardia, Tablet, RDY, Metformin, Abdominal pain, AstraZeneca, Liver, NSE, Plasma, Kidney, Risk, XR, Periodic breathing, Death, NYSE, Full, Generic drug, Copper, Medical device, Saxagliptin

Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.

Key Points: 
  • Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.
  • Please click here to see the full prescribing information, including boxed warning: https://drreddys.com/pil/150092247-PIL-Saxagl-Met-HCL-ER-Tab-US_V3_fn.pdf .
  • Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL.
  • (5.1)
    If lactic acidosis is suspected, discontinue saxagliptin and metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting.

Equity Income ETF, TGLR, Starts Trading Today Through Partnership Between Tuttle Capital Management and Laffer Tengler Investments

Retrieved on: 
Tuesday, August 8, 2023
Other Professional Services, Asset Management, Professional Services, Finance, Partnership, Chicago Board Options Exchange, RDY, Adviser, Morning Star, LTI, Relative, ETF, CBOE, CIO, Growth, PSN, Security (finance)

The Laffer Tengler Equity Income ETF, (CBOE: TGLR), will start trading today at the Chicago Board Options Exchange through a partnership with Tuttle Capital Management and Laffer Tengler Investments.

Key Points: 
  • The Laffer Tengler Equity Income ETF, (CBOE: TGLR), will start trading today at the Chicago Board Options Exchange through a partnership with Tuttle Capital Management and Laffer Tengler Investments.
  • The ETF is actively managed and will invest in high-quality, large-cap stocks that have strong earnings and dividend growth potential.
  • These indicators, both pioneered by the Laffer Tengler (LTI) team are supported by LTI’s rigorous and proprietary 12 Fundamental Factor research approach.
  • TGLR offers exposure to the Laffer Tengler Equity Income Strategy, run by media personality Nancy Tengler, that had previously only been available in separately managed accounts to wealth management and institutional investors.

iBUYPOWER and Fractal Design Announce Partnership with a New Lineup of Custom and Ready to Ship RDY Gaming PCs

Retrieved on: 
Tuesday, July 25, 2023
Partnership, AMD, RDY, Fractal, Fractal Design, Marketing, Personal computer, CPU, XTX, NVIDIA, SKU, Intel, LOS, GPU, Video game, Online shopping

LOS ANGELES, July 25, 2023 /PRNewswire/ -- iBUYPOWER (iBP), a leading manufacturer of high-performance custom gaming PCs, today, announced its partnership and expanded product offering with Fractal Design, a world renowned, award-winning Scandinavian company known for innovative and clean aesthetic design philosophy within the premium PC case and accessory category.

Key Points: 
  • "We are proud to present a new and extensive selection of clean and sophisticated case choices from Fractal Design to the iBUYPOWER audience," said Jeffrey Cheng, Sr. Director of Sales and Marketing at iBUYPOWER.
  • "Fractal Design is pleased to add our signature blend of performance and aesthetics to iBUYPOWER's extensive catalogue of products," said Andrew Leibman, Fractal Design North America Marketing Director.
  • Fractal Design cases will also be made available through the iBUYPOWER Custom Configurator for customers wishing to customize a system.
  • iBUYPOWER and Fractal Design systems are currently available from iBUYPOWER.com ranging from $1,749 and $2,499 depending on RDY SKU.